Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 10/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4640167 | 0.91 | ESR1 (0.57) | ESR1 | |
| SCHEMBL4639556 | 0.90 | ESR1 (0.42) | CYP19A1ESR1DRD2DRD4DRD3 | |
| SCHEMBL4639606 | 0.90 | ESR1 (0.41) | CYP19A1ESR1DRD2DRD4DRD3 | |
| SCHEMBL4639760 | 0.89 | ESR1 (0.45) | CYP19A1ESR1 | |
| SCHEMBL6152455 | 0.89 | CYP19A1 (0.44) | CYP19A1ESR1DRD2DRD4DRD3 | |
| SCHEMBL4640636 | 0.86 | ESR1 (0.45) | ESR1 | |
| SCHEMBL5422253 | 0.85 | ESR1 (0.64) | CYP19A1ESR1DRD2DRD4DRD3 | |
| SCHEMBL6153596 | 0.81 | CYP19A1 (0.51) | CYP19A1ESR1DRD2DRD4DRD3 | |
| SCHEMBL4640144 | 0.81 | ESR1 (0.64) | CYP19A1ESR1DRD2DRD4DRD3 | |
| SCHEMBL4639650 | 0.80 | ESR1 (0.42) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497277-A1 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003089422-A1 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |